The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 456-462

  Dresser, Linda D ^a   Rybak, Michael J ^a,b,c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b Department of Pharmacy   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CHLORAMPHENICOL; CL 331002; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; GENTAMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; LINCOMYCIN; LINEZOLID; MACROLIDE; MINOCYCLINE; NAFCILLIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIOSTASIS; CLINICAL TRIAL; COMPETITIVE INHIBITION; CROSS RESISTANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; POSTANTIBIOTIC EFFECT; REVIEW; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; TONGUE DISEASE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; DRUG RESISTANCE, MICROBIAL; GRAM-POSITIVE BACTERIA; HUMANS; MEDLINE; MICROBIAL SENSITIVITY TESTS; OXAZOLES; OXAZOLIDINONES;

EID: 0031966368     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of J-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40(4):839-45.
2. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996;40(3):720-6.
3. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997;41(2):465-7.
4. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U-100592 and U-100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1996;40(3):799-801.
5. Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996;39:673-9.
6. Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Potent water soluble prodrugs of the oxazolidinone antibacterial agent eperezolid. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy (abstr F23). Washington, DC: American Society for Microbiology, 1997.
7. Eustice DC, Feldman PA, Zajac I, Slee AM. Mechanism of action of DuP 721 : inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988;32(8):1218-22.
8. Lin AH, Dunyak DS, Buysse JM, Marotti KR. The oxazolidinone U100592 blocks translation initiation by binding to ribosomes. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy (abstr C101). Washington, DC: American Society for Microbiology, 1996.
9. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41(10): 2127-31.
10. Shinbarger DL. Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41(10):2132-6.
11. Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1988;32(9):1341-6.
12. Ford CW, Hamel JC, Wilson DM, et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1996;40(6):1508-13.
13. Ashtekar DR, Costa-Periera R, Shrinivasan T, lyyer R, Vishvanathan N, Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent; in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 1991;14:465-71.
14. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40(7):1745-7.
15. Mercier RC, Penzak SR, Rybak MJ. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41(11): 2573-5.
16. Hamel JC, Stapert D, Moerman JK, Ford CW. Experimental therapy of monomicrobic and polymicrobic soft tissue infections with U-100766 and U-100592, two new oxazolidinone antibiotics. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy (abstr F232). Washington, DC: American Society for Microbiology, 1996.
17. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activity and postantibiotic effect of oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecium. Antimicrob Agents Chemother 1998;43(3):721-4.
18. Stalker DJ, Wajszczuk CP, Bans DH. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14.5 days. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy (abstr A115). Washington, DC: American Society for Microbiology, 1997.
19. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance, and pharmacokinetics after intravenous dosing twice daily for 7.5 days. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy (abstr A116). Washington, DC: American Society for Microbiology, 1997.
20. Andes D, Vesga O, Batts D, Craig WA. Pharmacodynamic activity of an oxazolidinone in an animal infection model. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy (abstr F233). Washington, DC: American Society for Microbiology, 1996.